Company Overview
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies designed for the treatment of cancer and autoimmune diseases. The company functions within the Healthcare sector and specifically the Biotechnology industry, where its activities are centered on creating a pipeline of multiple allogeneic CAR T cell product candidates that utilize protein engineering. In terms of scale, Allogene Therapeutics reports a market capitalization of $538.75M while employing a workforce of 150 individuals. The absence of reported annual revenue figures alongside a market cap of $538.75M indicates that the company is in a pre-revenue or early-stage development phase where valuation is driven primarily by pipeline potential rather than current financial performance. This operational scale and valuation structure suggest the company is still in the investment phase of its lifecycle, relying on external capital to advance its research and development efforts before achieving significant commercial revenue generation.
Financial Health
The company reports no reported revenue for the trailing twelve months, resulting in a net income of $-190,886,000 and an EBITDA of $-194,574,000. The gap between zero revenue and a net income loss of $-190,886,000 reveals a cost structure dominated by high operational expenses related to research, development, and clinical trial activities rather than cost of goods sold or operating overhead. Free cash flow stands at $-80,727,000, which signifies that the company is consuming cash reserves to fund its operations and development programs, thereby limiting immediate financial flexibility for dividend payments or large-scale acquisitions. Analysis of the three reported margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, each indicating that the company has not yet achieved profitability or positive operational leverage. Regarding balance sheet leverage, Allogene holds $250.21M in cash against $83.25M in debt, resulting in a debt-to-equity ratio of 28.46. Although the company carries significant debt relative to equity, the substantial cash position provides a buffer, though the high debt-to-equity figure technically classifies the leverage as elevated relative to a traditional cash-rich company. The current ratio is 7.93, which indicates a robust short-term liquidity position with current assets significantly exceeding current liabilities. Return on equity is -53.4% and return on assets is -26.8%, metrics that reveal management is currently generating losses on the capital invested and assets held rather than positive returns.
Valuation Assessment
Valuation metrics for the company include a P/E ratio (TTM) listed as N/A due to lack of earnings, and a forward P/E of -2.95, implying that future earnings projections are also negative or that the stock price is priced against anticipated losses. The price-to-book ratio is 1.73, indicating that the market values the company at a premium of 73% above its book value, likely reflecting the intangible value of its intellectual property and clinical pipeline. The price-to-sales ratio is N/A and the EV/EBITDA is -1.91, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable in the conventional sense for a pre-revenue biotechnology firm. The stock has traded between a 52-week high of $2.80 and a 52-week low of $0.86; without a specific current price provided in the data, the valuation context relies on these historical bounds to show the stock's recent volatility range. The beta value is 0.50, which means the stock exhibits less volatility relative to the broader market, moving with half the magnitude of market swings. This lower beta suggests the asset may be less sensitive to general market fluctuations compared to larger cap equities, although the negative earnings metrics complicate standard risk-adjusted valuation comparisons.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet generated consistent revenue streams to calculate growth rates. Since earnings are negative at $-190,886,000, earnings cannot be growing faster than revenue in a traditional sense, as the primary focus remains on converting research into commercial products rather than scaling existing sales. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings, or rather the capital base, are being reinvested into growth initiatives rather than distributed to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation, with the entire financial structure oriented toward funding future product candidates and achieving commercialization milestones.